obesity drugs glp-1 news today health pharma october 2025 Outlook for obesity in 2025: more Dozens of new obesity drugs

Confirmatory testing using GC-MS or LC-MS/MS methodology is standard practice for employment drug testing and is explicitly required in DOT and federal workplace programs before any adverse action can be taken

10,23,24 Similarly, there was no increased risk of pancreatic cancer associated with GLP-1RAs in a large cohort study and a 2020 meta-analysis

Additional information Enhanced Digital Features To view enhanced digital features for this article go to Electronic supplementary material Below is the link to the electronic supplementary material

[DOI] [PubMed] [Google Scholar] 177.Brubaker P.L., Drucker D.J

10.1016/s0140-6736(87)91194-9 37 LanghansW

Mizumoto J